Edwards Lifesciences Co. (NYSE:EW) Shares Sold by WD Rutherford LLC

WD Rutherford LLC lessened its holdings in Edwards Lifesciences Co. (NYSE:EW - Free Report) by 48.4% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 9,482 shares of the medical research company's stock after selling 8,893 shares during the quarter. WD Rutherford LLC's holdings in Edwards Lifesciences were worth $702,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Bowman & Co S.C. increased its stake in shares of Edwards Lifesciences by 1.2% during the 4th quarter. Bowman & Co S.C. now owns 12,487 shares of the medical research company's stock worth $924,000 after purchasing an additional 148 shares in the last quarter. Mount Yale Investment Advisors LLC increased its stake in shares of Edwards Lifesciences by 1.9% during the 4th quarter. Mount Yale Investment Advisors LLC now owns 8,563 shares of the medical research company's stock worth $634,000 after purchasing an additional 162 shares in the last quarter. JFS Wealth Advisors LLC increased its stake in shares of Edwards Lifesciences by 31.1% during the 3rd quarter. JFS Wealth Advisors LLC now owns 700 shares of the medical research company's stock worth $46,000 after purchasing an additional 166 shares in the last quarter. Seascape Capital Management increased its stake in shares of Edwards Lifesciences by 0.5% during the 3rd quarter. Seascape Capital Management now owns 32,989 shares of the medical research company's stock worth $2,177,000 after purchasing an additional 174 shares in the last quarter. Finally, Cooper Financial Group increased its stake in shares of Edwards Lifesciences by 2.8% during the 4th quarter. Cooper Financial Group now owns 6,466 shares of the medical research company's stock worth $479,000 after purchasing an additional 175 shares in the last quarter. Hedge funds and other institutional investors own 79.46% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on EW shares. Stifel Nicolaus raised shares of Edwards Lifesciences from a "hold" rating to a "buy" rating and raised their price objective for the stock from $75.00 to $90.00 in a research note on Thursday, January 30th. Citigroup lifted their target price on shares of Edwards Lifesciences from $81.00 to $83.00 and gave the stock a "buy" rating in a research note on Wednesday, December 11th. The Goldman Sachs Group lifted their target price on shares of Edwards Lifesciences from $81.00 to $90.00 and gave the stock a "buy" rating in a research note on Thursday, December 5th. Barclays lifted their target price on shares of Edwards Lifesciences from $88.00 to $90.00 and gave the stock an "overweight" rating in a research note on Thursday, February 13th. Finally, Evercore ISI lowered their target price on shares of Edwards Lifesciences from $75.00 to $73.00 and set an "in-line" rating for the company in a research note on Wednesday, February 12th. One investment analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and twelve have issued a buy rating to the company's stock. Based on data from MarketBeat.com, Edwards Lifesciences has a consensus rating of "Hold" and an average price target of $79.95.

Insiders Place Their Bets

In other news, Director Steven R. Loranger sold 5,739 shares of the business's stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $76.42, for a total value of $438,574.38. Following the completion of the sale, the director now owns 60,372 shares of the company's stock, valued at approximately $4,613,628.24. The trade was a 8.68 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Scott B. Ullem sold 11,250 shares of the business's stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $75.76, for a total transaction of $852,300.00. Following the completion of the sale, the chief financial officer now directly owns 30,561 shares of the company's stock, valued at $2,315,301.36. The trade was a 26.91 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 26,489 shares of company stock worth $2,002,829 in the last quarter. 1.27% of the stock is owned by corporate insiders.

Edwards Lifesciences Stock Down 1.2 %

EW stock traded down $0.95 during trading on Wednesday, reaching $74.73. The stock had a trading volume of 3,023,259 shares, compared to its average volume of 4,526,352. Edwards Lifesciences Co. has a 1-year low of $58.93 and a 1-year high of $96.12. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The company has a market capitalization of $44.07 billion, a P/E ratio of 10.72, a PEG ratio of 4.92 and a beta of 1.10. The firm has a fifty day moving average price of $72.82 and a 200 day moving average price of $69.79.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings data on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, topping analysts' consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. On average, equities analysts anticipate that Edwards Lifesciences Co. will post 2.45 earnings per share for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.